Search BEIGF
BeOne Medicines Ltd.
Nasdaq, OTC · CIK 1651308
Last close21.95
Daily change+0.00 (0.00%)
10 Years gain+30.79%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BEIGF · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
89.9Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue12
Quarterly Revenue45
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality22.1 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics3.3 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 3.9315 percentage points.
Operating leverageOperating margin improved by 26.4619 percentage points.
ROIC expansionROIC improved by 39.4496 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM56.49%OK
Revenue CAGR 3Y55.69%OK
Gross Margin88.18%OK
Operating Margin13.89%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC26.09%OK
Incremental Operating Margin 3Y53.54%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y4.16%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $5.34B | $4.67B | $447.14M | $1.13B | $941.74M | 87.49% | 8.37% | 17.63% | 25.94% | 1.47B |
| 2025 FY Dec 31, 2024 | $3.81B | $3.22B | -$568.20M | -$140.63M | -$633.29M | 84.41% | -14.91% | -16.62% | -30.21% | 1.37B |
| 2025 FY Dec 31, 2023 | $2.46B | $2.08B | -$1.21B | -$1.16B | -$1.72B | 84.55% | -49.12% | -69.93% | -116.67% | 1.36B |
| 2024 FY Dec 31, 2022 | $1.42B | $1.13B | -$1.79B | -$1.50B | -$1.82B | 79.77% | -126.4% | -128.68% | -532.26% | 1.34B |
| 2023 FY Dec 31, 2021 | $1.18B | $1.01B | -$1.44B | -$1.30B | -$1.56B | 85.98% | -122.31% | -132.76% | n/a | 1.21B |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $5.95B | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-052878, 0001628280-25-049824 |
| Revenue Growth TTM | 56.49% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-052878, 0001628280-25-049824 |
| Revenue CAGR 3Y | 55.69% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-011946 |
| Revenue CAGR 5Y | 76.85% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-011946 |
| Gross Profit CAGR 3Y | 60.55% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-011946 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-052878, 0001628280-25-049824 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 88.18% | Gross Profit / Revenue | OK | 0001628280-26-052878, 0001628280-25-049824 |
| Operating Margin | 13.89% | Operating Income / Revenue | OK | 0001628280-26-052878, 0001628280-25-049824 |
| ROIC | 26.09% | NOPAT / Average Invested Capital | OK | 0001628280-26-052878, 0001628280-25-049824 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-052878 |
| Current Ratio | 3.41x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 6.46x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-052878 |
| Revenue per Diluted Share | $3.95 | Revenue / Diluted Shares | OK | 0001628280-26-052878, 0001628280-25-049824 |